VE-822 1232416-25-9

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight: 463.55 VE-822 is an ATR inhibitor with IC50 of 19 nM.


VE-822 (80 nM) attenuates ATR signaling pathway and reduces survival in
tumor cells in response to XRT and gemcitabine. VE-822 (80 nM)
attenuates ATR signaling in normal cells without enhancing radiation and
gemcitabine killing in normal cells. VE-822 (80 nM) increases
XRT-induced residual γH2AX and 53BP1 foci compared with XRT in MiaPaCa-2
and PSN-1 cells. VE-822 (80 nM) pre-treatment decreases Rad51 foci
after XRT in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) alone increases
the G1-phase-fraction in MiaPaCa-2 and PSN-1 cells.


VE-822 (80 nM)
abrogates XRT enriched G2/M-phase-fraction in MiaPaCa-2 and PSN-1 cells.
VE-822 has little effect alone, while VE-822 (80 nM) combined with XRT
and/or gemcitabine enhances early and late Apoptosis in PSN-1 cells that
is strongest in the triple combination. VE-822 increases tumor response to DNA damaging agents associated with blockade of pChk1 Ser345.






VE-822 (60 mg/kg) inhibits phospho-Ser-345-Chk1 in mice bearing PSN-1
tumors after DNA-damaging agents. VE-822 (60 mg/kg) combined with XTR
doubles the time for tumors to grow to 600 mm3 of XRT alone
in mice bearing both PSN-1 and MiaPaCa-2 tumors. VE-822 (60 mg/kg) added
to the combination of gemcitabine and XRT substantially prolongs the
tumor growth delay compared with the Gem+XRT1 group n mice bearing both
PSN-1 tumors. VE-822 (60 mg/kg) combined with XRT1 increases uptake in
tumors by 44% compared with XRT1, suggesting that addition of VE-822
increased γH2AX phosphorylation and persistence of DNA Damage caused by
XRT.


Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

Species	Baboon	Dog	Monkey	Rabbit	Guinea pig	Rat	Hamster	Mouse
Weight (kg)	12	10	3	1.8	0.4	0.15	0.08	0.02
Body Surface Area (m2)	0.6	0.5	0.24	0.15	0.05	0.025	0.02	0.007
Km factor	20	20	12	12	8	6	5	3

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B Km
	Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×	mouse Km(3)	= 11.2 mg/kg
	rat Km(6)

Chemical Information

Molecular Weight (MW)	463.55
Formula	C24H25N5O3S
CAS No.	1232416-25-9

Storage	3 years -20℃Powder
	6 months-80℃in solvent (DMSO, water, etc.)
Synonyms	VX970

Solubility (25°C) *	In vitro	DMSO	36 mg/mL (77.66 mM)
		Water	<1 mg/mL (
		Ethanol	<1 mg/mL (
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Name	2-Pyrazinamine, 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-

Molarity Calculator
Dilution Calculator
Molecular Weight Calculator

Contact us if you need more details on 1232416-25-9 VE-822. We are ready to answer your questions on packaging, logistics, certification or any other aspects about 1232416-25-9、VE-822 1232416-25-9. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : PI3K/Akt/mTOR > ATM/ATR Inhibitor